ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

FREQUENCY OF PAIN SEVERITY AND SUCCESS OF LOCAL ANESTHESIA DURING ACCESS CAVITY AND PULPECTOMY IN PATIENTS WITH IRREVERSIBLE PULPITIS

AUTHORS:

Sheba Ramzan, Madiha Zaighum, Kelash Kumar, Mowaffaq Abdullmomen Al Absi

ABSTRACT:

Introduction: In teeth with symptomatic irreversible pulpitis Inferior alveolar nerve block (IANB) is frequently used to anesthetize mandibular teeth for endodontic treatment. Researches has shown a high failure rate for IANB in teeth with symptomatic irreversible pulpitis. Therefore, anesthetizing posterior mandibular teeth with irreversible pulpitis has been a challenge for the clinicians. Aim/objective: The objective of this randomized clinical trial was to evaluate the frequency of pain severity in patients with irreversible pulpitis in mandibular molars as IANB irrespective of local anesthetic agent. Study design: Randomized control trial. Setting: ISRA dental college Hyderabad Material & Methods: 192 patients diagnosed with irreversible pulpitis in mandibular molars took part in the study with 61% female and 39% male patients. After taking informed consent, local anesthesia was administered and endodontic procedure was started. Visual Analogue Scale (VAS) has been used to measure the frequency of pain severity during access cavity and pulpectomy. Results: The VAS results showed that during access cavity, 66% patients reported no pain, 16% reported mild pain, 12% moderate pain and 6% reported severe pain. Whereas, during pulpectomy, 57% patients reported no pain, 20% mild pain, 16% moderate pain and 7% severe pain with the mean pain score during access cavity and pulpectomy was 1.50 with SDĀ±.50131 with p value <0.05. Conclusion: The study showed that patient with irreversible pulpitis in mandibular molars reported less frequency of pain during access cavity than pulpectomy during endodontic procedure. Key words: Local Anesthesia, Irreversible Pulpitis, Access Cavity, Pulpectomy, Anesthetic Efficacy.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.